123
Views
7
CrossRef citations to date
0
Altmetric
Special Report

Biological and nonbiological complex drugs for multiple sclerosis in Latin America: regulations and risk management

, , , , , , , , , , , , & show all

References

  • Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther 2010;87:157-9
  • Varkony H, Weinstein V, Klinger E, et al. The glatiramoid class of immunomodulator drugs. Expert Opin Pharmacother 2009;10:657-68
  • Johnson KP. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol 2010;6:643-60
  • Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-19
  • Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
  • Chugh PK, Roy V. Biosimilars: current scientific and regulatory considerations. Curr Clin Pharmacol 2014;9:53-63
  • Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-8; 33
  • Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 2013;13:153-6
  • Cai XY, Thomas J, Cullen C, Gouty D. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis 2012;4:2169-77
  • Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003;348:601-8
  • Schellekens H. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 2005;18:473-80
  • Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014;16:22-6
  • Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol 2003;112:15-21
  • US Food and Administration. The patient protection and affordable care act. Available from: www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm [Accessed 30 March 2015]
  • European Medicines Agency. Guidelines on biosimilar products. Available from: www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp#Overarchingbiosimilarguidelines [Accessed 30 March 2105]
  • Biotechnology Industry Organization. Norma Oficial Mexicana PROY-NOM-177-SSA1. 2013. Available from: www.bio.org/sites/default/files/BIO%20Comments%20espa%C3%B1ol_0.pdf [Last accessed 30 March 2015]
  • US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf [Accessed 31 January 2015]
  • Choy E, Jacobs IA. Biosimilar safety considerations in clinical practice. Semin Oncol 2014;41(Suppl 1):S3-14
  • Engelberg AB, Kesselheim AS, Avorn J. Balancing innovation, access, and profits–market exclusivity for biologics. N Engl J Med 2009;361(20):1917-19

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.